FDA actions in brief

Thalidomide (Thalomid, Celgene) was approved in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma.

FDA approved 2 higher dose formulations of valsartan/hydrochlorothiazide (Diovan HCT, Novartis) for the treatment of hypertension. The combination tablets will now be available in 320/12.5 mg and 320/25 mg doses.

FDA approved infliximab (Remicade, Centocor) to treat children aged 6 to 17 years with active Crohn's disease.